Wilson's disease: clinical management and therapy

Brewer, 2001

Scheinberg, 1984, vol. 23

Schilsky, 1996, Wilson disease: genetic basis of copper toxicity and natural history, Semin Liver Dis, 16, 83, 10.1055/s-2007-1007221

Bull, 1993, The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene, Nat Genet, 5, 327, 10.1038/ng1293-327

Tanzi, 1993, The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene, Nat Genet, 5, 344, 10.1038/ng1293-344

Yamaguchi, 1993, Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease, Biochem Biophys Res Commun, 197, 271, 10.1006/bbrc.1993.2471

Brewer, 1999, Diagnosis and treatment of Wilson's disease, Semin Neurol, 19, 261, 10.1055/s-2008-1040842

Walshe, 1956, Penicillamine, a new oral therapy for Wilson's disease, Am J Med, 21, 487, 10.1016/0002-9343(56)90066-3

Brewer, 1987, Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy, Arch Neurol, 44, 490, 10.1001/archneur.1987.00520170020016

Brewer, 1992, Wilson disease, Medicine, 71, 139, 10.1097/00005792-199205000-00004

Walshe, 1982, Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride, Lancet, 1, 643, 10.1016/S0140-6736(82)92201-2

Brewer, 2003, Double blind study of initial therapy of neurological Wilson's disease (abstract), J Invest Med, 51

Brewer, 1998, Treatment of Wilson's disease with zinc: XV long-term follow-up studies, J Lab Clin Med, 132, 264, 10.1016/S0022-2143(98)90039-7

Hall, 1979, Intestinal metallothionein and the mutual antagonism between copper and zinc in the rat, J Inorg Biochem, 11, 57, 10.1016/S0162-0134(00)80054-9

Menard, 1981, Regulation of intestinal metallothionein biosynthesis in rats by dietary zinc, J Nutr, 111, 1353, 10.1093/jn/111.8.1353

Oestreicher, 1985, Copper and zinc absorption in the rat: mechanism of mutual antagonism, J Nutr, 115, 159, 10.1093/jn/115.2.159

Lee, 1989, Treatment of Wilson's disease with zinc. VII. Protection of the liver from copper toxicity by zinc-induced metallothionein in a rat model, J Lab Clin Med, 114, 639

Yuzbasiyan-Gurkan, 1992, Treatment of Wilson's disease with zinc: X. Intestinal metallothionein induction, J Lab Clin Med, 120, 380

Mills, 1981, Effects of molybdate, sulfide, and tetrathiomolybdate on copper metabolism in rats, J Inorg Biochem, 14, 189, 10.1016/S0162-0134(00)80000-8

Bremner, 1982, Copper metabolism in rats given di- or trithiomolybdates, J Inorg Biochem, 16, 109, 10.1016/S0162-0134(00)80219-6

Mills, 1981, Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate, J Inorg Biochem, 14, 163, 10.1016/S0162-0134(00)80037-9

Gooneratne, 1981, An investigation of the effects of intravenous administration of thiomolybdate on copper metabolism in chronic Cu-poisoned sheep, Br J Nutr, 46, 469, 10.1079/BJN19810055

Mason, 1990, The biochemical pathogenesis of molybdenum-induced copper deficiency syndromes in ruminants: towards the final chapter, Ir Vet J, 43, 18

Brewer, 1991, Initial therapy of patients with Wilson's disease with tetrathiomolybdate, Arch Neurol, 48, 42, 10.1001/archneur.1991.00530130050019

Brewer, 1994, Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients, Arch Neurol, 51, 545, 10.1001/archneur.1994.00540180023009

Brewer, 1996, Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy, Arch Neurol, 53, 1017, 10.1001/archneur.1996.00550100103019

Brewer, 2003, Treatment of Wilson disease with ammonium tetrathiomolybdate. III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy, Arch Neurol, 60, 379, 10.1001/archneur.60.3.379

Askari, 2003, Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc, J Lab Clin Med, 142, 385, 10.1016/S0022-2143(03)00157-4

Nazer, 1986, Wilson's disease: clinical presentation and use of prognostic index, Gut, 27, 1377, 10.1136/gut.27.11.1377

Brewer, 1993, Treatment of Wilson's disease with zinc. XI. Interaction with other anticopper agents, J Am Coll Nutr, 12, 26, 10.1080/07315724.1993.10718278

Hoogenraad, 1987, Management of Wilson's disease with zinc sulfate. Experience in a series of 27 patients, J Neurol Sci, 77, 137, 10.1016/0022-510X(87)90116-X

Brewer, 2000, Treatment of Wilson's disease with zinc XVII. Treatment during pregnancy, Hepatology, 31, 364, 10.1002/hep.510310216

Mjolnerod, 1971, Congenital connective tissue defect probably due to D-penicillamine treatment in pregnancy, Lancet, 1, 673, 10.1016/S0140-6736(71)92681-X

Solomon, 1977, Neonatal abnormalities associated with d-penicillamine treatment during pregnancy, N Engl J Med, 296, 54, 10.1056/NEJM197701062960123

Keen, 1982

Kannan, 2001, Effect of zinc treatment for Wilson's disease on zinc concentration in breast milk (abstract), J Trace Elem Exp Med, 14, 283

Brewer, 2001, Treatment of Wilson's disease with zinc XVI: treatment during the pediatric years, J Lab Clin Med, 137, 191, 10.1067/mlc.2001.113037

Portala K. Psychopathology in Wilson's disease. Uppsala Thesis; 2001.

Portala, 2001, Personality traits in treated Wilson's disease determined by means of the Karolinska Scales of Personality (KSP), Eur Psychiatry, 16, 362, 10.1016/S0924-9338(01)00592-2

Portala, 2002, Sleep in patients with treated Wilson's disease. A questionnaire study, Nord J Psychiatry, 56, 291, 10.1080/08039480260242796

Portala, 2001, Pattern of neuropsychological deficits in patients with treated Wilson's disease, Eur Arch Psychiatry Clin Neurosci, 251, 262, 10.1007/PL00007543

Portala, 2000, Psychopathology in treated Wilson's disease determined by means of CPRS expert and self-ratings, Acta Psychiatrica Scandinavica, 101, 104, 10.1034/j.1600-0447.2000.90085.x